

Francesco Frassoni

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7784981/publications.pdf>

Version: 2024-02-01

228
papers

20,741
citations

22548

61
h-index

11946

139
g-index

231
all docs

231
docs citations

231
times ranked

18091
citing authors

#	ARTICLE	IF	CITATIONS
1	Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants. <i>Science</i> , 2002, 295, 2097-2100.	6.0	3,071
2	Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. <i>Lancet, The</i> , 2008, 371, 1579-1586.	6.3	2,474
3	Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. <i>Blood</i> , 2005, 106, 1755-1761.	0.6	1,318
4	Transplants of Umbilical-Cord Blood or Bone Marrow from Unrelated Donors in Adults with Acute Leukemia. <i>New England Journal of Medicine</i> , 2004, 351, 2276-2285.	13.9	1,058
5	Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. <i>Lancet, The</i> , 1998, 352, 1087-1092.	6.3	609
6	Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. <i>Blood</i> , 2003, 102, 814-819.	0.6	515
7	Mesenchymal stem cells effectively modulate pathogenic immune response in experimental autoimmune encephalomyelitis. <i>Annals of Neurology</i> , 2007, 61, 219-227.	2.8	450
8	Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype. <i>Haematologica</i> , 2005, 90, 516-25.	1.7	444
9	Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). <i>Leukemia</i> , 2005, 19, 2304-2312.	3.3	417
10	Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT. <i>Blood</i> , 2001, 98, 972-978.	0.6	342
11	A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation. <i>Blood</i> , 2008, 112, 3574-3581.	0.6	261
12	Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase I/II study. <i>Lancet Oncology, The</i> , 2008, 9, 831-839.	5.1	244
13	Mesenchymal stem cells impair in vivo T-cell priming by dendritic cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 17384-17389.	3.3	241
14	Phenotypic and functional heterogeneity of human NK cells developing after umbilical cord blood transplantation: a role for human cytomegalovirus?. <i>Blood</i> , 2012, 119, 399-410.	0.6	241
15	Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time. <i>Bone Marrow Transplantation</i> , 2005, 36, 757-769.	1.3	232
16	Human Mesenchymal Stem Cells Promote Survival of T Cells in a Quiescent State. <i>Stem Cells</i> , 2007, 25, 1753-1760.	1.4	231
17	Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis. <i>Blood</i> , 2003, 102, 4255-4260.	0.6	217
18	Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid-refractory, grade III acute graft-versus-host disease. <i>British Journal of Haematology</i> , 2013, 163, 501-509.	1.2	213

#	ARTICLE	IF	CITATIONS
19	The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group. <i>Multiple Sclerosis Journal</i> , 2010, 16, 503-510.	1.4	212
20	Diagnostic and clinical relevance of the number of circulating CD34+ cells in myelofibrosis with myeloid metaplasia. <i>Blood</i> , 2001, 98, 3249-3255.	0.6	197
21	Blood Stream Infections in Allogeneic Hematopoietic Stem Cell Transplant Recipients: Reemergence of Gram-Negative Rods and Increasing Antibiotic Resistance. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 47-53.	2.0	189
22	Human Cytomegalovirus Infection Promotes Rapid Maturation of NK Cells Expressing Activating Killer Ig-like Receptor in Patients Transplanted with NKG2C ^{hi} Umbilical Cord Blood. <i>Journal of Immunology</i> , 2014, 192, 1471-1479.	0.4	176
23	Second Allogeneic Bone Marrow Transplantation in Acute Leukemia: Results of a Survey by the European Cooperative Group for Blood and Marrow Transplantation. <i>Journal of Clinical Oncology</i> , 2001, 19, 3675-3684.	0.8	173
24	Treatment With Granulocyte Colony-Stimulating Factor After Allogeneic Bone Marrow Transplantation for Acute Leukemia Increases the Risk of Graft-Versus-Host Disease and Death: A Study From the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Journal of Clinical Oncology</i> , 2004, 22, 416-423.	0.8	173
25	Quality of life in 244 recipients of allogeneic bone marrow transplantation. <i>British Journal of Haematology</i> , 2000, 110, 614-619.	1.2	164
26	Multipotent mesenchymal stromal cells from amniotic fluid: solid perspectives for clinical application. <i>Haematologica</i> , 2008, 93, 339-346.	1.7	159
27	Human mesenchymal stem cells inhibit antibody production induced in vitro by allostimulation. <i>Nephrology Dialysis Transplantation</i> , 2007, 23, 1196-1202.	0.4	142
28	Graft-versus-host disease and outcome in HLA-identical sibling transplantations for chronic myeloid leukemia. <i>Blood</i> , 2002, 100, 3877-3886.	0.6	141
29	Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type. <i>Bone Marrow Transplantation</i> , 2010, 45, 458-463.	1.3	141
30	Factors influencing haematological recovery after allogeneic haemopoietic stem cell transplants: graft-versus-host disease, donor type, cytomegalovirus infections and cell dose. <i>British Journal of Haematology</i> , 2001, 112, 219-227.	1.2	137
31	Transplantation of Peripheral Blood Stem Cells as Compared With Bone Marrow From HLA-Identical Siblings in Adult Patients With Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2002, 20, 4655-4664.	0.8	136
32	Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 1997, 20, 553-560.	1.3	134
33	Relapse after allogeneic bone marrow transplantation for acute leukaemia: a survey by the E.B.M.T. of 117 cases. <i>British Journal of Haematology</i> , 1988, 70, 317-320.	1.2	117
34	T-cell suppression mediated by mesenchymal stem cells is deficient in patients with severe aplastic anemia. <i>Experimental Hematology</i> , 2005, 33, 819-827.	0.2	109
35	Effect of centre on outcome of bone-marrow transplantation for acute myeloid leukaemia. <i>Lancet</i> , 2000, 355, 1393-1398.	6.3	99
36	Selective effect of feline leukaemia virus on early erythroid precursors. <i>Nature</i> , 1982, 296, 156-158.	13.7	97

#	ARTICLE	IF	CITATIONS
37	Hematopoietic stem cell transplantation for hematological malignancies in Europe. <i>Leukemia</i> , 2003, 17, 941-959.	3.3	93
38	Achieving a Major Molecular Response at the Time of a Complete Cytogenetic Response (CCgR) Predicts a Better Duration of CCgR in Imatinib-Treated Chronic Myeloid Leukemia Patients. <i>Clinical Cancer Research</i> , 2006, 12, 3037-3042.	3.2	90
39	Factors predicting response and graft-versus-host disease after donor lymphocyte infusions: a study on 593 infusions. <i>Bone Marrow Transplantation</i> , 2003, 31, 687-693.	1.3	89
40	Transplant-related mortality and long-term graft function are significantly influenced by cell dose in patients undergoing allogeneic marrow transplantation. <i>Blood</i> , 2002, 100, 3930-3934.	0.6	88
41	MiRNAs and piRNAs from bone marrow mesenchymal stem cell extracellular vesicles induce cell survival and inhibit cell differentiation of cord blood hematopoietic stem cells: a new insight in transplantation. <i>Oncotarget</i> , 2016, 7, 6676-6692.	0.8	86
42	Recurrence of Ph ⁺ 2-Positive Leukemia in Donor Cells after Marrow Transplantation for Chronic Granulocytic Leukemia. <i>New England Journal of Medicine</i> , 1984, 310, 903-906.	13.9	83
43	In vivo B-cell depletion with rituximab for alternative donor hemopoietic SCT. <i>Bone Marrow Transplantation</i> , 2012, 47, 101-106.	1.3	83
44	Unbalanced X ⁱⁿ chromosome inactivation in haemopoietic cells from normal women. <i>British Journal of Haematology</i> , 1998, 102, 996-1003.	1.2	81
45	Endothelial colony-forming cells from patients with chronic myeloproliferative disorders lack the disease-specific molecular clonality marker. <i>Blood</i> , 2009, 114, 3127-3130.	0.6	79
46	The Ultrastructural Localization of Factor VIII-Antigen in Human Platelets, Megakaryocytes and Endothelial Cells Utilizing a Ferritin-labelled Antibody. <i>British Journal of Haematology</i> , 1978, 39, 209-213.	1.2	78
47	Cord blood transplantation provides better reconstitution of hematopoietic reservoir compared with bone marrow transplantation. <i>Blood</i> , 2003, 102, 1138-1141.	0.6	76
48	Intra ⁱⁿ bone marrow injection of bone marrow and cord blood cells: an alternative way of transplantation associated with a higher seeding efficiency. <i>Experimental Hematology</i> , 2004, 32, 782-787.	0.2	76
49	Diabetes Impairs the Vascular Recruitment of Normal Stem Cells by Oxidant Damage, Reversed by Increases in pAMPK, Heme Oxygenase-1, and Adiponectin. <i>Stem Cells</i> , 2009, 27, 399-407.	1.4	75
50	Identical Outcome After Autologous or Allogeneic Genoidentical Hematopoietic Stem-Cell Transplantation in First Remission of Acute Myelocytic Leukemia Carrying Inversion 16 or t(8;21): A Retrospective Study From the European Cooperative Group for Blood and Marrow Transplantation. <i>Journal of Clinical Oncology</i> , 2008, 26, 3183-3188.	0.8	73
51	Antileukemia effects of xanthohumol in Bcr/Abl-transformed cells involve nuclear factor- κ B and p53 modulation. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 2692-2702.	1.9	73
52	Donor lymphocyte infusions for the treatment of minimal residual disease in acute leukemia. <i>Blood</i> , 2007, 109, 5063-5064.	0.6	72
53	p38 MAPK and JNK Antagonistically Control Senescence and Cytoplasmic p16INK4A Expression in Doxorubicin-Treated Endothelial Progenitor Cells. <i>PLoS ONE</i> , 2010, 5, e15583.	1.1	70
54	IN VIVO MOBILIZATION OF KARYOTYPICALLY NORMAL PERIPHERAL BLOOD PROGENITOR CELLS IN HIGH-RISK MDS, SECONDARY OR THERAPY-RELATED ACUTE MYELOGENOUS LEUKAEMIA. <i>British Journal of Haematology</i> , 1996, 95, 127-130.	1.2	68

#	ARTICLE	IF	CITATIONS
55	Mobilization and transplantation of Philadelphia-negative peripheral-blood progenitor cells early in chronic myelogenous leukemia.. Journal of Clinical Oncology, 1997, 15, 1575-1582.	0.8	68
56	Unrelated Cord Blood Transplantation. Transplantation, 2013, 95, 1284-1291.	0.5	66
57	The Assessment of the Hematopoietic Reservoir After Immunosuppressive Therapy or Bone Marrow Transplantation in Severe Aplastic Anemia. Blood, 1998, 91, 1959-1965.	0.6	65
58	Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe. Bone Marrow Transplantation, 2002, 29, 639-646.	1.3	65
59	Relevance of Bone Marrow Cell Dose on Allogeneic Transplantation Outcomes for Patients With Acute Myeloid Leukemia in First Complete Remission: Results of a European Survey. Journal of Clinical Oncology, 2002, 20, 4324-4330.	0.8	65
60	No impact of high-dose cytarabine on the outcome of patients transplanted for acute myeloblastic leukaemia in first remission. British Journal of Haematology, 2000, 110, 308-314.	1.2	64
61	ABO COMPATIBILITY AND ACUTE GRAFT-VERSUS-HOST DISEASE FOLLOWING ALLOGENEIC BONE MARROW TRANSPLANTATION. Transplantation, 1988, 45, 1091-1093.	0.5	63
62	Stem cells in inflammatory demyelinating disorders: a dual role for immunosuppression and neuroprotection. Expert Opinion on Biological Therapy, 2006, 6, 17-22.	1.4	63
63	Exosomes from human mesenchymal stem cells conduct aerobic metabolism in term and preterm newborn infants. FASEB Journal, 2016, 30, 1416-1424.	0.2	63
64	Is there a graft-versus-leukaemia effect in the absence of graft-versus-host disease in patients undergoing bone marrow transplantation for acute leukaemia?. British Journal of Haematology, 2000, 111, 1130-1137.	1.2	63
65	Helical tomotherapy targeting total bone marrow after total body irradiation for patients with relapsed acute leukemia undergoing an allogeneic stem cell transplant. Radiotherapy and Oncology, 2011, 98, 382-386.	0.3	62
66	Rituximab Treatment for Epstein-Barr Virus DNAemia after Alternative-Donor Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2011, 17, 901-907.	2.0	59
67	Mesenchymal Stem Cells Infusion Prevents Acute Cellular Rejection in Rat Kidney Transplantation. Transplantation Proceedings, 2010, 42, 1331-1335.	0.3	58
68	Hematopoietic stem cell transplantation for adults with acute promyelocytic leukemia in the ATRA era: a survey of the European Cooperative Group for Blood and Marrow Transplantation. Bone Marrow Transplantation, 2007, 39, 461-469.	1.3	55
69	Reduced intensity thiotepa-cyclophosphamide conditioning for allogeneic haemopoietic stem cell transplants (HSCT) in patients up to 60 years of age. British Journal of Haematology, 2000, 109, 716-721.	1.2	54
70	Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: influence of dose and stem cell source shows better outcome with rich marrow. Blood, 2003, 102, 3043-3051.	0.6	52
71	Mesenchymal Stem Cells Protective Effect in Adriamycin Model of Nephropathy. Cell Transplantation, 2008, 17, 1157-1167.	1.2	52
72	Human Mesenchymal Stem Cells and Cyclosporin A Exert a Synergistic Suppressive Effect on In Vitro Activation of Alloantigen-Specific Cytotoxic Lymphocytes. Biology of Blood and Marrow Transplantation, 2005, 11, 1031-1032.	2.0	51

#	ARTICLE	IF	CITATIONS
73	Estimating the whole bone-marrow asset in humans by a computational approach to integrated PET/CT imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 1326-1338.	3.3	51
74	Prophylactic antithymocyte globulin reduces the risk of chronic graft-versus-host disease in alternative-donor bone marrow transplants. <i>Biology of Blood and Marrow Transplantation</i> , 2002, 8, 656-661.	2.0	50
75	HLA-identical sibling allogeneic peripheral blood stem cell transplantation with reduced intensity conditioning compared to autologous peripheral blood stem cell transplantation for elderly patients with de novo acute myeloid leukemia. <i>Leukemia</i> , 2007, 21, 129-135.	3.3	50
76	Patients with acute lymphoblastic leukaemia allografted with a matched unrelated donor may have a lower survival with a peripheral blood stem cell graft compared to bone marrow. <i>Bone Marrow Transplantation</i> , 2003, 31, 23-29.	1.3	49
77	Clinical scale ex vivo expansion of cord blood-derived outgrowth endothelial progenitor cells is associated with high incidence of karyotype aberrations. <i>Experimental Hematology</i> , 2008, 36, 340-349.	0.2	49
78	High dose bolus methylprednisolone for the treatment of acute graft versus host disease. <i>Blut</i> , 1983, 46, 125-132.	1.2	48
79	Which Is the Most Suitable and Effective Route of Administration for Mesenchymal Stem Cell-Based Immunomodulation Therapy in Experimental Kidney Transplantation: Endovenous or Arterial?. <i>Transplantation Proceedings</i> , 2010, 42, 1336-1340.	0.3	48
80	The combined effect of total body irradiation (TBI) and cyclosporin A (CyA) on the risk of relapse in patients with acute myeloid leukaemia undergoing allogeneic bone marrow transplantation. <i>British Journal of Haematology</i> , 2000, 108, 99-104.	1.2	46
81	Massive chemotherapy with non-frozen autologous bone marrow transplantation in 13 cases of refractory Hodgkin's disease. <i>European Journal of Cancer & Clinical Oncology</i> , 1985, 21, 607-613.	0.9	45
82	Pre-emptive therapy of acute graft-versus-host disease: a pilot study with antithymocyte globulin (ATG). <i>Bone Marrow Transplantation</i> , 2001, 28, 1093-1096.	1.3	45
83	The retroviral transduction of HOXC4 into human CD34+ cells induces an in vitro expansion of clonogenic and early progenitors. <i>Experimental Hematology</i> , 2000, 28, 569-574.	0.2	44
84	Dose-effect relationship for cataract induction after single-dose total body irradiation and bone marrow transplantation for acute leukemia. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 52, 1367-1374.	0.4	43
85	Donor multipotent mesenchymal stromal cells may engraft in pediatric patients given either cord blood or bone marrow transplantation. <i>Experimental Hematology</i> , 2006, 34, 934-942.	0.2	42
86	Induction and Survival of Binucleated Purkinje Neurons by Selective Damage and Aging. <i>Journal of Neuroscience</i> , 2007, 27, 9885-9892.	1.7	42
87	Late Development of FcÎ³R3neg Adaptive Natural Killer Cells Upon Human Cytomegalovirus Reactivation in Umbilical Cord Blood Transplantation Recipients. <i>Frontiers in Immunology</i> , 2018, 9, 1050.	2.2	42
88	Discrete Changes in Glucose Metabolism Define Aging. <i>Scientific Reports</i> , 2019, 9, 10347.	1.6	42
89	Total body irradiation in acute myeloid leukemia and chronic myelogenous leukemia: influence of dose and dose-rate on leukemia relapse. <i>International Journal of Radiation Oncology Biology Physics</i> , 1989, 17, 547-552.	0.4	41
90	Haemopoietic colony formation (BFU-E, GM-CFC) during the development of pure red cell hypoplasia induced in the cat by feline leukaemia virus. <i>Leukemia Research</i> , 1983, 7, 103-116.	0.4	40

#	ARTICLE	IF	CITATIONS
91	Allogeneic bone marrow transplant or second autograft in patients with acute leukemia who relapse after an autograft. <i>Bone Marrow Transplantation</i> , 1999, 24, 389-396.	1.3	39
92	Hematopoietic stem cell transplantation for de novo acute megakaryocytic leukemia in first complete remission: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2005, 105, 405-409.	0.6	39
93	Deficient reconstitution of early progenitors after allogeneic bone marrow transplantation. <i>Bone Marrow Transplantation</i> , 1997, 19, 1011-1017.	1.3	38
94	Mesenchymal stromal cells, from indifferent spectators to principal actors. Are we going to witness a revolution in the scenario of allograft and immune-mediated disorders?. <i>Haematologica</i> , 2007, 92, 872-877.	1.7	37
95	Twelve Years Experience with High-Dose Therapy and Autologous Stem Cell Transplantation for High-Risk Hodgkin's Disease Patients in First Remission After MOPP/ABVD Chemotherapy. <i>Leukemia and Lymphoma</i> , 1996, 21, 63-70.	0.6	36
96	Molecular Follow-Up of Disease Progression and Interferon Therapy in Chronic Myelocytic Leukemia. <i>Blood</i> , 1997, 90, 4918-4923.	0.6	36
97	Association of Human Development Index with rates and outcomes of hematopoietic stem cell transplantation for patients with acute leukemia. <i>Blood</i> , 2010, 116, 122-128.	0.6	36
98	Competition between recipient and donor cells after bone marrow transplantation for chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 1988, 69, 471-475.	1.2	36
99	Bone marrow transplantation for chronic myeloid leukemia (CML) from unrelated and sibling donors: single center experience. <i>Bone Marrow Transplantation</i> , 1997, 20, 1057-1062.	1.3	34
100	Fractionated total body irradiation in marrow transplantation for leukaemia. <i>British Journal of Haematology</i> , 1983, 55, 547-554.	1.2	33
101	Feasibility and recent improvement of autologous stem cell transplantation for acute myelocytic leukaemia in patients over 60 years of age: importance of the source of stem cells. <i>British Journal of Haematology</i> , 2000, 110, 887-893.	1.2	32
102	A novel Bim-BH3-derived Bcl-XL inhibitor: Biochemical characterization, in vitro, in vivo and ex-vivo anti-leukemic activity. <i>Cell Cycle</i> , 2008, 7, 3211-3224.	1.3	32
103	The dismal outcome in patients with acute leukaemia who relapse after an autograft is improved if a second autograft or a matched allograft is performed. <i>Bone Marrow Transplantation</i> , 2000, 25, 1053-1058.	1.3	31
104	Increased risk of leukemia relapse with high dose cyclosporine after allogeneic marrow transplantation for acute leukemia: 10 year follow-up of a randomized study. <i>Blood</i> , 2001, 98, 3174-3174.	0.6	31
105	CMV Infection after Transplant from Cord Blood Compared to Other Alternative Donors: The Importance of Donor-Negative CMV Serostatus. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 92-99.	2.0	31
106	High Frequency of Endothelial Colony Forming Cells Marks a Non-Active Myeloproliferative Neoplasm with High Risk of Splanchnic Vein Thrombosis. <i>PLoS ONE</i> , 2010, 5, e15277.	1.1	30
107	Improving the outcome of umbilical cord blood transplantation through ex vivo expansion or graft manipulation. <i>Cytotherapy</i> , 2015, 17, 730-738.	0.3	30
108	High-dose chemotherapy and non-frozen autologous bone marrow transplantation in relapsed advanced lymphomas or those resistant to conventional chemotherapy. <i>Cancer</i> , 1984, 54, 2836-2839.	2.0	29

#	ARTICLE	IF	CITATIONS
109	Autologous and allogeneic bone marrow transplantation in acute myeloid leukemia in first complete remission: an update of the Genoa experience with 159 patients. <i>Annals of Hematology</i> , 1992, 64, 128-131.	0.8	29
110	Freshly dissociated fetal neural stem/progenitor cells do not turn into blood. <i>Molecular and Cellular Neurosciences</i> , 2003, 22, 179-187.	1.0	29
111	The intra-bone marrow injection of cord blood cells extends the possibility of transplantation to the majority of patients with malignant hematopoietic diseases. <i>Best Practice and Research in Clinical Haematology</i> , 2010, 23, 237-244.	0.7	29
112	The effect of total body irradiation dose and chronic graft-versus-host disease on leukaemic relapse after allogeneic bone marrow transplantation. <i>British Journal of Haematology</i> , 1989, 73, 211-216.	1.2	28
113	Restoration of normal polyclonal haemopoiesis in patients with chronic myeloid leukaemia autografted with Ph ⁺ negative peripheral stem cells. <i>British Journal of Haematology</i> , 1994, 87, 867-870.	1.2	28
114	Factors influencing outcome and incidence of long-term complications in children who underwent autologous stem cell transplantation for acute myeloid leukemia in first complete remission. <i>Blood</i> , 2003, 101, 1611-1619.	0.6	28
115	Coexistence of normal and clonal haemopoiesis in aplastic anaemia patients treated with immunosuppressive therapy. <i>British Journal of Haematology</i> , 1999, 107, 505-511.	1.2	27
116	Chromosome studies in patients with Philadelphia chromosome-positive chronic myeloid leukemia submitted to bone marrow transplantation—Results of a European cooperative study. <i>Cancer Genetics and Cytogenetics</i> , 1987, 26, 5-13.	1.0	26
117	A revised day +7 predictive score for transplant-related mortality: serum cholinesterase, total protein, blood urea nitrogen, $\hat{\gamma}$ glutamyl transferase, donor type and cell dose. <i>Bone Marrow Transplantation</i> , 2003, 32, 205-211.	1.3	26
118	Mesenchymal stromal cells improve renal injury in anti-Thy 1 nephritis by modulating inflammatory cytokines and scatter factors. <i>Clinical Science</i> , 2011, 120, 25-36.	1.8	26
119	Mesenchymal stem cells from preterm to term newborns undergo a significant switch from anaerobic glycolysis to the oxidative phosphorylation. <i>Cellular and Molecular Life Sciences</i> , 2018, 75, 889-903.	2.4	26
120	Philadelphia-chromosome-negative peripheral blood stem cells can be mobilized in the early phase of recovery after a myelosuppressive chemotherapy in Philadelphia-chromosome-positive acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 1995, 89, 535-538.	1.2	25
121	Strong antileukemic effect of chronic graft-versus-host disease in allogeneic marrow transplant recipients having acute leukemia treated with methotrexate and cyclosporine. <i>Transplantation Proceedings</i> , 1997, 29, 733-734.	0.3	25
122	Total body irradiation correlates with chronic graft versus host disease and affects prognosis of patients with acute lymphoblastic leukemia receiving an HLA identical allogeneic bone marrow transplant. <i>International Journal of Radiation Oncology Biology Physics</i> , 1999, 43, 497-503.	0.4	25
123	Nonhuman primate allogeneic hematopoietic stem cell transplantation by intraosseus vs intravenous injection: Engraftment, donor cell distribution, and mechanistic basis. <i>Experimental Hematology</i> , 2008, 36, 1556-1566.	0.2	25
124	The impact of center experience on results of reduced intensity: allogeneic hematopoietic SCT for AML. An analysis from the Acute Leukemia Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2013, 48, 238-242.	1.3	25
125	Phenotypic and functional analysis of the HLA-class ^{II} -specific inhibitory receptors of natural killer cells isolated from peripheral blood of patients undergoing bone marrow transplantation from matched unrelated donors. <i>The Hematology Journal</i> , 2000, 1, 136-144.	2.0	25
126	Evidence of cytogenetic and molecular remission by allogeneic cells after immunosuppressive therapy alone. <i>British Journal of Haematology</i> , 1998, 103, 565-567.	1.2	24

#	ARTICLE	IF	CITATIONS
127	Prediction of response to imatinib by prospective quantitation of BCR-ABL transcript in late chronic phase chronic myeloid leukemia patients. <i>Annals of Oncology</i> , 2006, 17, 495-502.	0.6	24
128	Adult Advanced Chronic Lymphocytic Leukemia: Computational Analysis of Whole-Body CT Documents a Bone Structure Alteration. <i>Radiology</i> , 2014, 271, 805-813.	3.6	24
129	Preterm Cord Blood Contains a Higher Proportion of Immature Hematopoietic Progenitors Compared to Term Samples. <i>PLoS ONE</i> , 2015, 10, e0138680.	1.1	24
130	Generation of CFU-C suppressor T cells in vitro: V. A. MULTISTEP PROCESS. <i>British Journal of Haematology</i> , 1982, 52, 421-427.	1.2	23
131	Donor-recipient incompatibility at CD31-codon 563 is a major risk factor for acute graft-versus-host disease after allogeneic bone marrow transplantation from a human leucocyte antigen-matched donor. <i>British Journal of Haematology</i> , 2001, 114, 951-953.	1.2	23
132	Hematopoietic stem cell transplantation for de novo erythroleukemia: a study of the European Group for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2002, 100, 3135-3140.	0.6	23
133	Mesenchymal Stromal Cells. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 53-57.	2.0	23
134	Mesenchymal stromal cells reset the scatter factor system and cytokine network in experimental kidney transplantation. <i>BMC Immunology</i> , 2014, 15, 44.	0.9	23
135	Allogeneic cell transplant expands bone marrow distribution by colonizing previously abandoned areas: an FDG PET/CT analysis. <i>Blood</i> , 2015, 125, 4095-4102.	0.6	23
136	Issues in the manufacture and transplantation of genetically modified hematopoietic stem cells. <i>Current Opinion in Hematology</i> , 2000, 7, 364-377.	1.2	22
137	Improved outcome in young adults with de novo acute myeloid leukemia in first remission, undergoing an allogeneic bone marrow transplant. <i>Bone Marrow Transplantation</i> , 2007, 40, 349-354.	1.3	22
138	Bone marrow transplantation for chronic granulocytic leukemia. <i>Cancer</i> , 1986, 58, 2307-2311.	2.0	21
139	Karyotype evolution of Ph positive chronic myelogenous leukemia patients relapsed in advanced phases of the disease after allogeneic bone marrow transplantation. <i>Cancer Genetics and Cytogenetics</i> , 1991, 57, 69-78.	1.0	21
140	Contact with the bone marrow microenvironment readdresses the fate of transplanted hematopoietic stem cells. <i>Experimental Hematology</i> , 2010, 38, 968-977.	0.2	21
141	Bone marrow or peripheral blood as a source of stem cells for allogeneic transplants. <i>Current Opinion in Hematology</i> , 2000, 7, 343-347.	1.2	20
142	Risk assessment in adult acute lymphoblastic leukaemia before early haemopoietic stem cell transplantation with a geno-identical donor: an easy clinical prognostic score to identify patients who benefit most from allogeneic haemopoietic stem cell transplantation. <i>Leukemia</i> , 2003, 17, 1596-1599.	3.3	20
143	Is there a place for autologous bone marrow transplantation in chronic myeloid leukemia?. <i>Stem Cells</i> , 1993, 11, 1-3.	1.4	19
144	Randomised studies in acute myeloid leukaemia: the double truth. <i>Bone Marrow Transplantation</i> , 2000, 25, 471-472.	1.3	19

#	ARTICLE	IF	CITATIONS
145	Adoptive immunotherapy mediated by ex vivo expanded natural killer T cells against CD1d-expressing lymphoid neoplasms. <i>Haematologica</i> , 2009, 94, 967-974.	1.7	19
146	Effective mobilization of Philadelphia-chromosome-negative cells in chronic myelogenous leukaemia patients using a less intensive regimen. <i>British Journal of Haematology</i> , 1998, 100, 445-448.	1.2	18
147	Chromosome studies in patients with acute nonlymphocytic or acute lymphocytic leukemia submitted to bone marrow transplantation—Results of a European cooperative study. <i>Cancer Genetics and Cytogenetics</i> , 1987, 26, 51-58.	1.0	17
148	Selective overshoot of Philadelphia-negative blood hemopoietic cells after intensive idarubicin-containing regimen and their repopulating capacity after reinfusion. <i>Stem Cells</i> , 1993, 11, 67-72.	1.4	17
149	Idarubicin, Intermediate-Dose Cytarabine, Etoposide, and Granulocyte-Colony-Stimulating Factor Are Able to Recruit CD34+/HLA-DR-Cells During Early Hematopoietic Recovery in Accelerated and Chronic Phases of Chronic Myeloid Leukemia. <i>Stem Cells and Development</i> , 1994, 3, 199-202.	1.0	17
150	Splenic irradiation before bone marrow transplantation for chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 1996, 95, 494-500.	1.2	17
151	Competition between recipient and donor cells after bone marrow transplantation for chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 1988, 69, 471-475.	1.2	17
152	Aberrant activation of ROS1 represents a new molecular defect in chronic myelomonocytic leukemia. <i>Leukemia Research</i> , 2013, 37, 520-530.	0.4	17
153	High Dose BCNU Followed by Autologous Bone Marrow Infusion in Glioblastoma Multiforme. <i>Tumori</i> , 1981, 67, 473-475.	0.6	16
154	GRAFT-VERSUS-LEUKAEMIA EFFECT FOLLOWING ALLOGENEIC BONE MARROW TRANSPLANTATION. <i>British Journal of Haematology</i> , 1985, 61, 749-751.	1.2	15
155	Competitive survival/proliferation of normal and Ph1-positive haemopoietic cells. <i>British Journal of Haematology</i> , 1986, 63, 135-141.	1.2	15
156	In haematopoietic SCT for acute leukemia TBI impacts on relapse but not survival: results of a multicentre observational study. <i>Bone Marrow Transplantation</i> , 2013, 48, 908-914.	1.3	15
157	EphA3 targeting reduces in vitro adhesion and invasion and in vivo growth and angiogenesis of multiple myeloma cells. <i>Cellular Oncology (Dordrecht)</i> , 2017, 40, 483-496.	2.1	15
158	Cytogenetic follow-up after bone marrow transplantation for Philadelphia-positive chronic myeloid leukemia. <i>Cancer Genetics and Cytogenetics</i> , 1989, 42, 253-261.	1.0	14
159	Thiotepa-based reduced intensity conditioning regimen: a 10 year follow up. <i>Bone Marrow Transplantation</i> , 2007, 40, 1091-1093.	1.3	14
160	Results of syngeneic hematopoietic stem cell transplantation for acute leukemia: risk factors for outcomes of adults transplanted in first complete remission. <i>Haematologica</i> , 2008, 93, 834-841.	1.7	14
161	Deferasirox-Dependent Iron Chelation Enhances Mitochondrial Dysfunction and Restores p53 Signaling by Stabilization of p53 Family Members in Leukemic Cells. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7674.	1.8	14
162	Intravenous Monoclonal Antibody (BT 5/9) for the Treatment of Acute Graft-versus-Host Disease. <i>Acta Haematologica</i> , 1985, 73, 185-186.	0.7	13

#	ARTICLE	IF	CITATIONS
163	The relative spatial distribution of erythroid progenitor cells (BFUe and CFUe) in the normal mouse femur. <i>Cell Proliferation</i> , 1982, 15, 447-455.	2.4	12
164	Differential effects of the type of iron chelator on the absolute number of hematopoietic peripheral progenitors in patients with α -thalassemia major. <i>Haematologica</i> , 2013, 98, 555-559.	1.7	12
165	Clonal haematopoiesis is not prevalent in survivors of childhood cancer. <i>British Journal of Haematology</i> , 2018, 181, 537-539.	1.2	12
166	Acyclovir for the Treatment of Severe Aplastic Anemia. <i>New England Journal of Medicine</i> , 1984, 310, 1606-1607.	13.9	11
167	Variant Philadelphia translocations in CML: Correlation with fragile sites. <i>Cancer Genetics and Cytogenetics</i> , 1988, 31, 105-112.	1.0	11
168	Normal primitive haemopoietic progenitors are more frequent than their leukaemic counterpart in newly diagnosed patients with chronic myeloid leukaemia but rapidly decline with time. <i>British Journal of Haematology</i> , 1999, 104, 538-545.	1.2	11
169	Progenitor cells trapped in marrow filters can reduce GvHD and transplant mortality. <i>Bone Marrow Transplantation</i> , 2006, 38, 111-117.	1.3	11
170	Acute myelogenous leukemia with translocation t(8;21): A cytogenetic study of seven cases. <i>Cancer Genetics and Cytogenetics</i> , 1986, 20, 363-368.	1.0	10
171	Spontaneous exodus of high numbers of normal early progenitor cells (Ph ⁻ negative LTC ⁻ IC) in the peripheral blood of patients with chronic myeloid leukaemia at the beginning of the disease. <i>British Journal of Haematology</i> , 1997, 97, 94-98.	1.2	10
172	Allogeneic hemopoietic stem cell transplants for patients with relapsed acute leukemia: long-term outcome. <i>Bone Marrow Transplantation</i> , 2007, 39, 341-346.	1.3	10
173	Radiomics and Artificial Intelligence for Outcome Prediction in Multiple Myeloma Patients Undergoing Autologous Transplantation: A Feasibility Study with CT Data. <i>Diagnostics</i> , 2021, 11, 1759.	1.3	10
174	Efficient long-term maintenance of chronic myeloid leukemic cobblestone area forming cells on a murine stromal cell line. <i>Leukemia</i> , 1997, 11, 126-133.	3.3	9
175	Iron overload alters the energy metabolism in patients with myelodysplastic syndromes: results from the multicenter FISM BIOFER study. <i>Scientific Reports</i> , 2020, 10, 9156.	1.6	9
176	Variable but consistent pattern of Meningioma 1 gene (<i>MN1</i>) expression in different genetic subsets of acute myelogenous leukaemia and its potential use as a marker for minimal residual disease detection. <i>Oncotarget</i> , 2016, 7, 74082-74096.	0.8	9
177	Generation of CFU-C Suppressor T Cells. <i>Acta Haematologica</i> , 1983, 70, 163-169.	0.7	8
178	Idarubicin alone or in combination with citarabine and etoposide (3 + 3 + 5 protocol) in acute non-lymphoblastic leukaemia. <i>Leukemia Research</i> , 1985, 9, 631.	0.4	8
179	Serum cholinesterase is an early and sensitive marker of graft-versus host-disease (GVHD) and transplant-related mortality (TRM). <i>Bone Marrow Transplantation</i> , 2001, 28, 1041-1045.	1.3	8
180	Modified in vitro conditions for cord blood ⁻ derived long-term culture-initiating cells. <i>Experimental Hematology</i> , 2001, 29, 309-314.	0.2	8

#	ARTICLE	IF	CITATIONS
181	Reassessing autotransplantation for acute myeloid leukaemia in first remission – a matched pair analysis of autologous marrow vs peripheral blood stem cells. <i>Bone Marrow Transplantation</i> , 2004, 33, 1209-1214.	1.3	8
182	Abnormalities of Na/K ATPase in Migraine With Aura. <i>Cephalalgia</i> , 2007, 27, 128-132.	1.8	8
183	Intrabone Transplant of Cord Blood Stem Cells Establishes a Local Engraftment Store: A Functional PET/FDG Study. <i>Journal of Biomedicine and Biotechnology</i> , 2012, 2012, 1-8.	3.0	8
184	Detection of BCR-ABL T315I mutation by peptide nucleic acid directed PCR clamping and by peptide nucleic acid FISH. <i>Biomarker Research</i> , 2015, 3, 15.	2.8	8
185	The Wilmsâ€™ tumor (WT 1) gene expression correlates with the International Prognostic Scoring System (IPSS) score in patients with myelofibrosis and it is a marker of response to therapy. <i>Cancer Medicine</i> , 2016, 5, 1650-1653.	1.3	8
186	Stem cells for multiple sclerosis: promises and reality. <i>Regenerative Medicine</i> , 2007, 2, 7-9.	0.8	7
187	A novel assay to detect calreticulin mutations in myeloproliferative neoplasms. <i>Oncotarget</i> , 2017, 8, 6399-6405.	0.8	7
188	Bone Marrow Transplantation (BMT) for Acute Nonlymphoid Leukemia (ANLL) in First Remission. <i>Acta Haematologica</i> , 1985, 74, 23-26.	0.7	6
189	Stem-cell mobilization for autografting in chronic myeloid leukemia. <i>Blood Reviews</i> , 1997, 11, 154-159.	2.8	6
190	Anti-T-cell globulin: an essential ingredient for haematopoietic cell transplantation?. <i>Lancet Oncology</i> , The, 2009, 10, 839.	5.1	6
191	Impact of length of cryopreservation and origin of cord blood units on hematologic recovery following cord blood transplantation. <i>Bone Marrow Transplantation</i> , 2015, 50, 818-821.	1.3	6
192	Splenic irradiation before hematopoietic stem cell transplantation for chronic myeloid leukemia: long-term follow-up of a prospective randomized study. <i>Annals of Hematology</i> , 2016, 95, 967-972.	0.8	6
193	In vitro tests in severe aplastic anaemia (SAA): a prospective study in 46 patients treated with immunosuppression. <i>British Journal of Haematology</i> , 1985, 59, 611-616.	1.2	5
194	Molecular analysis of Philadelphia-negative myeloproliferative syndromes with i(17q). <i>Cancer Genetics and Cytogenetics</i> , 1989, 43, 195-201.	1.0	5
195	Late complications of allogeneic bone marrow transplantation. <i>Medical Oncology and Tumor Pharmacotherapy</i> , 1991, 8, 261-263.	1.0	5
196	Autografting with Ph-negative progenitors in patients at diagnosis of chronic myeloid leukemia induces a prolonged prevalence of Ph-negative hemopoiesis. <i>Experimental Hematology</i> , 2000, 28, 210-215.	0.2	5
197	Identification of Biochemical and Molecular Markers of Early Aging in Childhood Cancer Survivors. <i>Cancers</i> , 2021, 13, 5214.	1.7	5
198	Mepartricin: A New Antifungal Agent for the Treatment of Disseminated Candida Infections in the Immunocompromised Host. <i>Acta Haematologica</i> , 1983, 69, 409-413.	0.7	4

#	ARTICLE	IF	CITATIONS
199	Total body irradiation before allogeneic and autologous bone marrow transplantation: A ten year Genoa experience. <i>Radiotherapy and Oncology</i> , 1990, 18, 135-138.	0.3	4
200	Splenic Irradiation before Bone Marrow Transplantation for Chronic Myeloid Leukemia: Update of a Prospective Randomized Study. <i>Leukemia and Lymphoma</i> , 1993, 11, 227-231.	0.6	4
201	Is minimal residual disease in the peripheral-blood stem-cell transplantation of chronic myelogenous leukemia important?. <i>Journal of Clinical Oncology</i> , 1997, 15, 3166-3167.	0.8	4
202	Association of ex-vivo expanded human mesenchymal stem cells and rhBMP-7 is highly effective in treating critical femoral defect in rats. <i>Journal of Orthopaedics and Traumatology</i> , 2007, 8, 49-54.	1.0	4
203	Design and application of a novel PNA probe for the detection at single cell level of JAK2V617F mutation in Myeloproliferative Neoplasms. <i>BMC Cancer</i> , 2013, 13, 348.	1.1	4
204	Transplantation Induces Profound Changes in the Transcriptional Asset of Hematopoietic Stem Cells: Identification of Specific Signatures Using Machine Learning Techniques. <i>Journal of Clinical Medicine</i> , 2020, 9, 1670.	1.0	4
205	Tobramycin versus Gentamicin, in Combination with Cephalotin and Carbenecillin, in Patients Undergoing Bone Marrow Transplantation. <i>Tumori</i> , 1981, 67, 525-532.	0.6	3
206	GM-CFC growth in chronic granulocytic leukaemia is not affected by a soluble inhibitor released by aplastic anaemia T-cells or mitogen-primed normal T-lymphocytes. <i>British Journal of Haematology</i> , 1982, 50, 647-653.	1.2	3
207	Human serum-dependent survival of GM-CFCs in vitro from patients with chronic granulocytic leukemia. <i>Leukemia Research</i> , 1987, 11, 3-6.	0.4	3
208	Normal and leukaemic haematopoiesis in bone marrow and peripheral blood of patients with chronic myeloid leukaemia. <i>Best Practice and Research in Clinical Haematology</i> , 1999, 12, 199-208.	0.7	3
209	Cyclosporin A (CyA) does not enhance CFUâ€ growth in patients with severe aplastic anaemia. <i>Scandinavian Journal of Haematology</i> , 1985, 34, 133-136.	0.0	3
210	CIRCULATING IMMUNE COMPLEXES IN ALLOGENEIC MARROW GRAFT RECIPIENTS. <i>Transplantation</i> , 1984, 38, 428-429.	0.5	2
211	T-Derived Colony-Inhibiting Activity: Partial Characterization and Mechanism of Action. <i>Acta Haematologica</i> , 1985, 74, 195-199.	0.7	2
212	The Use of Glycopeptides as Empiric Antibiotic Therapy in Febrile Neutropenic Patients: A Comparison Between Teicoplanin (TEI) and Vancomycin (VAN). <i>Leukemia and Lymphoma</i> , 1992, 7, 110-111.	0.6	2
213	Mobilization/transplantation of Ph1-negative blood progenitor cells in chronic myelogenous leukaemia. <i>Annals of Oncology</i> , 1996, 7, 19-22.	0.6	2
214	The laws covering in vitro fertilization and embryo research in Italy. <i>Bone Marrow Transplantation</i> , 2006, 38, 5-6.	1.3	2
215	SEX DIFFERENCES IN HUMAN LYMPHOCYTE Na,K-ATPase AS STUDIED BY LABELED OUABAIN BINDING. <i>International Journal of Neuroscience</i> , 2007, 117, 275-285.	0.8	2
216	Mesenchymal stem cells for acute graft-versus-host disease â€“ Authors' reply. <i>Lancet</i> , The, 2008, 372, 716.	6.3	2

#	ARTICLE	IF	CITATIONS
217	Autografting With Philadelphia Chromosome-â€“Negative Mobilized Hematopoietic Progenitor Cells in Chronic Myelogenous Leukemia. <i>Blood</i> , 1999, 93, 1534-1539.	0.6	2
218	Interferon-Î± protects Philadelphia-negative progenitors from exhaustion in chronic myeloid leukemia patients with cytogenetic response. <i>The Hematology Journal</i> , 2001, 2, 26-32.	2.0	2
219	Eradication of leukaemic marrow and prevention of leukaemia relapse with total body irradiation and bone marrow transplantation. <i>Medical Oncology and Tumor Pharmacotherapy</i> , 1991, 8, 189-201.	1.0	2
220	Relapse after allogeneic BMT for chronic myeloid leukemia (CML) may be sustained by a small number of leukemic â€“stem cellsâ€™: a hypothesis. <i>Bone Marrow Transplantation</i> , 1999, 24, 689-691.	1.3	1
221	Biologic and clinical aspects of autologous stem cell transplantation with mobilized peripheral blood cells in chronic myelogenous leukemia. <i>Current Oncology Reports</i> , 2000, 2, 144-151.	1.8	1
222	Intra-bone route of administration offers new perspectives for safer transplantation of hematopoietic stem cells. <i>Cytotherapy</i> , 2010, 12, 5-6.	0.3	1
223	The Assessment of the Hematopoietic Reservoir After Immunosuppressive Therapy or Bone Marrow Transplantation in Severe Aplastic Anemia. <i>Blood</i> , 1998, 91, 1959-1965.	0.6	1
224	Clinical Problems Associated with T Cell Depletion for Bone Marrow Transplantation. <i>Annals of the New York Academy of Sciences</i> , 1987, 511, 459-463.	1.8	0
225	Reply to Drs Caocci and Pisu. <i>Bone Marrow Transplantation</i> , 2006, 38, 830-831.	1.3	0
226	New possibilities to exploit the potentiality of cord blood cells in the context of transplantation. <i>Immunology Letters</i> , 2013, 155, 24-26.	1.1	0
227	Hematopoietic stem cell transplantation. <i>Current Opinion in Hematology</i> , 2000, 7, 331-332.	1.2	0
228	Hematopoietic stem cell transplantation. <i>Current Opinion in Hematology</i> , 2001, 8, 327-329.	1.2	0